Merck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive agreement to acquire Mirus Bio in a $600m (€500m) deal. The move aims to enhance Merck’s ...

Recognized as the leader in nucleic acid delivery technologies, Mirus Bio announces the first instrument added to their product portfolio, the Ingenio® EZporator® Electroporation System. Experts from ...

Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at around $600 million.